GGrantIndex
← Leaderboards

Farrah Kheradmand

Minneapolis Va Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$15,730,322
Attributed
$20,467,296
Total exposure
21
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,467,296 · 18
VA$0 · 3

By mechanism

R01$17,360,132 · 9
U19$1,409,292 · 1
T32$596,975 · 1
K02$498,150 · 1
K08$348,024 · 1
M01$254,723 · 5

Top collaborators

Most similar at Minneapolis Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Lung”

Research focus

LungResponseImmuneCellsChronicBaseImmune ResponseT-LymphocytePhenotypeSmokerLung DiseasesMediatingPulmonary EmphysemaCytokineInflammatoryChronic Obstructive Airway DiseaseInflammationCohortLung InflammationStructure Of Parenchyma Of LungIn VitroMolecularProteinsSmoke

Grant awards (80)

Detrimental Effects of B-Cell-Th17 Axis in Antiviral Immunity in Smokers.$799,998
R01 · FY2025 · HL · contact PI
BCM-Respiratory Research Training$300,639
T32 · FY2025 · HL · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2025 · VA
BCM-Respiratory Research Training$296,336
T32 · FY2024 · HL · contact PI
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC$0
I01 · FY2024 · VA · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2024 · VA
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2023 · VA
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$505,156
R01 · FY2022 · AI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2022 · VA
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$505,156
R01 · FY2021 · AI
IMPACC-MEDVAMC$327,994
R01 · FY2021 · AI
Innate and acquired immune responses in human COPD$0
I01 · FY2021 · VA · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2021 · VA
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$505,156
R01 · FY2020 · AI
Toxic Effects of Ecigs Following Transition From Conventional Cigarettes$447,532
R01 · FY2020 · ES · contact PI
Pathogenesis of Polymicrobial Cerebritis-Related Dementia$320,830
R01 · FY2020 · AI
Admin Suppl to examine the role of Vit E Acetate in ENDS$211,990
R01 · FY2020 · ES · contact PI
IMPACC-MEDVAMC$162,902
R01 · FY2020 · AI
Innate and acquired immune responses in human COPD$0
I01 · FY2020 · VA · contact PI
CMA:Pulmonary and Systemic Effects of Deployment Related Particulate Matter Exposures$0
I01 · FY2020 · VA
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$512,215
R01 · FY2019 · AI
Toxic Effects of Ecigs Following Transition From Conventional Cigarettes$462,377
R01 · FY2019 · ES · contact PI
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$380,056
R01 · FY2019 · AI
Innate and acquired immune responses in human COPD$0
I01 · FY2019 · VA · contact PI
FUNGAL PATHOGENESIS OF MODERATE TO SEVERE ASTHMA$555,952
R01 · FY2018 · AI
Toxic Effects of Ecigs Following Transition From Conventional Cigarettes$473,721
R01 · FY2018 · ES · contact PI
Innate and acquired immune responses in human COPD$0
I01 · FY2018 · VA · contact PI
Regulation of Innate and Acquired Immunity in Human COPD and Emphysema$0
I01 · FY2017 · VA · contact PI
Th1 and Th17 Mediators in Experimental Emphysema$391,250
R01 · FY2016 · HL · contact PI
Regulation of Innate and Acquired Immunity in Human COPD and Emphysema$0
I01 · FY2016 · VA · contact PI
Ancillary T Cell Based Studies in SPIROMICS$391,478
R01 · FY2015 · HL · contact PI
Th1 and Th17 Mediators in Experimental Emphysema$385,381
R01 · FY2015 · HL · contact PI
Regulation of Innate and Acquired Immunity in Human COPD and Emphysema$0
I01 · FY2015 · VA · contact PI
Ancillary T Cell Based Studies in SPIROMICS$393,907
R01 · FY2014 · HL · contact PI
Th1 and Th17 Mediators in Experimental Emphysema$383,425
R01 · FY2014 · HL · contact PI
Regulation of Innate and Acquired Immunity in Human COPD and Emphysema$0
I01 · FY2014 · VA · contact PI
Ancillary T Cell Based Studies in SPIROMICS$395,878
R01 · FY2013 · HL · contact PI
Th1 and Th17 Mediators in Experimental Emphysema$372,470
R01 · FY2013 · HL · contact PI
Ancillary T Cell Based Studies in SPIROMICS$381,470
R01 · FY2012 · HL · contact PI
Regulation of Innate and Adaptive Immunity in Human COPD and Emphysema$0
I01 · FY2012 · VA · contact PI
Molecular Phenotypes for Lung Diseases$687,318
R01 · FY2011 · HL
VIRAL-INDUCED T CELL RESPONSES IN COPD EXACERBATION PROTOCOL: LES COPD$62,926
M01 · FY2011 · RR · contact PI
Regulation of Innate and Adaptive Immunity in Human COPD and Emphysema$0
I01 · FY2011 · VA · contact PI
Regulation of Innate and Adaptive Immunity in Human COPD and Emphysema$0
I01 · FY2011 · VA · contact PI
Molecular Phenotypes for Lung Diseases$692,215
R01 · FY2010 · HL
Immune modulators of inflammation in servere COPD$435,346
R01 · FY2010 · HL · contact PI
The Role of Proteinases in Experimental Asthma$322,632
U19 · FY2010 · AI · contact PI
VIRAL-INDUCED T CELL RESPONSES IN COPD EXACERBATION PROTOCOL: LES COPD$69,816
M01 · FY2010 · RR · contact PI
Molecular Phenotypes for Lung Diseases$692,485
R01 · FY2009 · HL
Immune modulators of inflammation in servere COPD$411,039
R01 · FY2009 · HL · contact PI
Viral-induced T Cell Responses in COPD Exacerbation$371,320
R01 · FY2009 · HL · contact PI
The Role of Proteinases in Experimental Asthma$312,925
U19 · FY2009 · AI · contact PI
VIRAL-INDUCED T CELL RESPONSES IN COPD EXACERBATION PROTOCOL$49,178
M01 · FY2009 · RR · contact PI
Regulation of Innate and Adaptive Immunity in Human COPD and Emphysema$0
I01 · FY2009 · VA · contact PI
Molecular Phenotypes for Lung Diseases$697,014
R01 · FY2008 · HL
Viral-induced T Cell Responses in COPD Exacerbation$626,109
R01 · FY2008 · HL · contact PI
The Role of Proteinases in Experimental Asthma$292,264
U19 · FY2008 · AI · contact PI
VIRAL-INDUCED T CELL RESPONSES IN COPD EXACERBATION PROTOCOL: LES COPD$49,078
M01 · FY2008 · RR · contact PI
Viral-induced T Cell Responses in COPD Exacerbation$644,237
R01 · FY2007 · HL · contact PI
The Role of Proteinases in Experimental Asthma$248,452
U19 · FY2007 · AI · contact PI
The Role of Proteases in Lung Inflammation & Remodeling$99,630
K02 · FY2007 · HL · contact PI
LONGITUDINAL EXACERBATION STUDY OF COPD (LES COPD)$23,725
M01 · FY2007 · RR · contact PI
Viral-induced T Cell Responses in COPD Exacerbation$598,472
R01 · FY2006 · HL · contact PI
The Role of Proteinases in Experimental Asthma$233,019
U19 · FY2006 · AI · contact PI
The Role of Proteinases in Experimental Asthma$151,899
R01 · FY2006 · HL · contact PI
The Role of Proteases in Lung Inflammation & Remodeling$99,630
K02 · FY2006 · HL · contact PI
Viral-induced T Cell Responses in COPD Exacerbation$360,134
R01 · FY2005 · HL
Immune Modulators of Inflammation in Severe COPD$263,375
R01 · FY2005 · HL
The Role of Proteases in Lung Inflammation &Remodeling$99,630
K02 · FY2005 · HL
Immune Modulators of Inflammation in Severe COPD$263,375
R01 · FY2004 · HL
The Role of Proteases in Lung Inflammation &Remodeling$99,630
K02 · FY2004 · HL
Immune Modulators of Inflammation in Severe COPD$263,375
R01 · FY2003 · HL
Proteases in Lung Inflammation &Remodeling$99,630
K02 · FY2003 · HL
Immune Modulators of Inflammation in Severe COPD$263,375
R01 · FY2002 · HL
THE ROLE OF PROTEASES IN EXPERIMENTAL ASTHMA$224,250
R01 · FY2002 · HL
EPITHELIAL/MESENCHYMAL INTERACTIONS IN LUNG DEVELOPMENT$116,008
K08 · FY2002 · HL
THE ROLE OF PROTEASES IN EXPERIMENTAL ASTHMA$224,250
R01 · FY2001 · HL
EPITHELIAL/MESENCHYMAL INTERACTIONS IN LUNG DEVELOPMENT$116,008
K08 · FY2001 · HL
THE ROLE OF PROTEASES IN EXPERIMENTAL ASTHMA$224,250
R01 · FY2000 · HL
EPITHELIAL/MESENCHYMAL INTERACTIONS IN LUNG DEVELOPMENT$116,008
K08 · FY2000 · HL